Back to All Combinations
FGFR Alterations
Intermediate PrognosisGenes Involved
FGFR1
FGFR2
FGFR3
Treatment Implications
FGFR inhibitors approved in other tumors. CRC trials ongoing.
Recommended Treatments
Clinical trials
Standard therapy
Treatments to Avoid
No specific contraindications noted
Study References
NCI-MATCH
Key Statistics
2.00%
Prevalence in CRC
No
Targetable
Clinical Notes
FGFR2 fusions most actionable.
Information
Category: Rare Fusions
Evidence Level: Level 3
Last Updated: Dec 7, 2025
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.